April 13, 2017
resTORbio, Inc. (resTORbio), a subsidiary of PureTech Health (LSE: PRTC) pioneering the development of biopharmaceuticals to address aging-related diseases and conditions, today announced the appointment of Joan Mannick, M.D., as Chief Medical Officer.
resTORbio notes in this role, Joan Mannick, MD will lead research and development activities for resTORbio. The initial focus of resTORbio will be progressing a Phase 2b clinical-stage program targeting the mechanistic target of rapamycin complex 1 (mTORC1) pathway to treat conditions caused by immunosenescence. Dr. Mannick joins resTORbio from Novartis Institutes of Biomedical Research (NIBR), where she led the clinical-stage mTORC1 program licensed by resTORbio.
“We are thrilled to welcome Dr. Mannick to resTORbio as Chief Medical Officer,” said Chen Schor, PureTech Health Senior Executive & Chief Executive Officer of resTORbio. “The mTORC1 program led by Joan at Novartis forms the foundation for a new approach to address diseases and conditions related to aging, including immunosenescence. We plan to unveil additional data from our program in forthcoming publications, and we look forward to rapidly advancing this groundbreaking work through clinical development.”
Dr. Mannick joins resTORbio from Novartis, where she led the clinical program that targets pathways regulating aging to treat aging-related conditions. Prior to joining Novartis in 2010, Dr. Mannick was a Medical Director at Genzyme working in multiple therapeutic areas. Prior to Genzyme, Dr. Mannick was a faculty member at Harvard Medical School and University of Massachusetts Medical School. Her NIH-sponsored laboratory focused on the role of protein S-nitrosylation in the regulation of cellular function. Dr. Mannick received her A.B. from Harvard College and her M.D. from Harvard Medical School. She completed her residency in Internal Medicine at Brigham and Women’s Hospital and an Infectious Disease fellowship as part of the Harvard Combined Infectious Disease Program.
“I am very excited to join resTORbio and continue the development of the mTORC1 program. Two Phase 2a clinical studies have been completed with the program, and I am eager to move the program forward in development and initiate Phase 2b this year,” said Dr. Joan Mannick. “Based on the data we have generated to-date, I am confident in our clinical development plan and look forward to potentially improving the health of our aging population.”